
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Collaboration
TegMine Collaborates with Boehringer Ingelheim on 2-Factor Antibody System for Cancer
Details : The collaboration aims to advance cancer treatment with the 2-Factor Antibody System targeting tumor-associated glycan epitopes.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
September 23, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Collaboration
